- Over 75 biotech firms have adopted Veeva Basics, highlighting its strong market penetration.
- Veeva Systems (VEEV, Financial) expands product range with new applications for clinical trial management and regulatory submissions.
- Rapid deployment and scalability make Veeva Basics a preferred choice in North America and Europe.
Veeva Systems (VEEV) has announced that more than 75 biotechnology companies are currently utilizing Veeva Basics, a pre-configured and pre-validated software platform designed for clinical, regulatory, and quality operations. This rapid adoption indicates a significant shift in the market towards comprehensive solutions that support scalability and growth for emerging biotech firms.
To further enhance its offerings, Veeva Systems has introduced two new applications: Veeva CTMS Basics, which focuses on clinical trial management, and Veeva Submissions Publishing Basics, targeting regulatory submissions. These additions aim to address the operational challenges faced by biotech companies, providing them with industry-leading software solutions that can be implemented within a matter of weeks.
Available in North America and Europe, Veeva Basics leverages the Vault Platform allowing customers to maintain their current functionalities while scaling their technology infrastructure as they expand. This approach provides an efficient upgrade path for growing companies and captures a broader customer base by offering accessible advanced software solutions.
Testimonials from users such as Corbus Pharmaceuticals, Scancell, and Terns Pharmaceuticals highlight the tangible benefits of Veeva Basics, including increased operational efficiency, enhanced regulatory compliance, and speedy implementation. The platform is set to further solidify Veeva Systems' presence in the biotech sector as it continues to meet the evolving needs of fast-growing companies.
